开云app官网登录入口网页版-官方正版

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2023-07-10 ms7000000867418816 来自四川省

审稿速度:2.0 | 投稿命中率:75.0
偏重的研究方向：二代测序;结核;微生物
经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收

96 0

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2014-04-07 manyang52

审稿速度:2.0 | 投稿命中率:50.0
经验分享：还是比较快的2个月给初审结果

520 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2016-09-29 ms5047990432985118

最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。

170 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2022-12-21 ms9000001908843367 来自浙江省

偏重的研究方向：微生物
经验分享：With editor 2个月了没有动静，准备撤稿

0 0

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2022-03-14 ms8000002007049985

这个一般从投稿到接受需要多久啊

91 0

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2021-12-29 ms6000000264964247

如何判断两种药物之间是协同作用还是相加作用？

90 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2021-12-27 乌云背后的幸福线

上传文章有什么要求？

94 1

展开1条回复

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2020-08-03 Juldez822

审稿速度:3.0 | 投稿命中率:25.0
经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊

148 0

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2019-03-07 124963ffm19(暂无昵称)

请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表:
if又降了，两个月前看还是2.401，现在是2.341，伤心……

wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……

247 0

[GetPortalCommentsPageByObjectIdResponse(id=2147358, encodeId=2953214e3583a, content=审稿速度:2.0 | 投稿命中率:75.0 偏重的研究方向：二代测序;结核;微生物 经验分享：5.2投稿，5.10送审，十天后返修意见回来，6.14返修回，7.9接收, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=96, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fe568406062, createdName=ms7000000867418816, createdTime=Mon Jul 10 21:49:02 CST 2023, time=2023-07-10, status=1, ipAttribution=四川省), GetPortalCommentsPageByObjectIdResponse(id=502190, encodeId=dd1b50219098, content=审稿速度:2.0 | 投稿命中率:50.0 经验分享：还是比较快的2个月给初审结果, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=520, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=5b9392088, createdName=manyang52, createdTime=Mon Apr 07 09:50:00 CST 2014, time=2014-04-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=834032, encodeId=7281834032b2, content=最近投中一篇文章，不容易，需要有点儿新的内容。速度也还可以。 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=170, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=79425414132, createdName=ms5047990432985118, createdTime=Thu Sep 29 09:56:08 CST 2016, time=2016-09-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2106923, encodeId=1685210692382, content=偏重的研究方向：微生物 经验分享：With editor 2个月了没有动静，准备撤稿, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8ebb6164598, createdName=ms9000001908843367, createdTime=Wed Dec 21 12:30:03 CST 2022, time=2022-12-21, status=1, ipAttribution=浙江省), GetPortalCommentsPageByObjectIdResponse(id=1202619, encodeId=9dfe120261918, content=这个一般从投稿到接受需要多久啊 , beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=f5be6390259, createdName=ms8000002007049985, createdTime=Mon Mar 14 23:04:42 CST 2022, time=2022-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089322, encodeId=0eea108932211, content=如何判断两种药物之间是协同作用还是相加作用？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=90, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=1ff65466529, createdName=ms6000000264964247, createdTime=Wed Dec 29 14:52:48 CST 2021, time=2021-12-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1089321, encodeId=be281089321e6, content=上传文章有什么要求？, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=94, replyNumber=1, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210512/3d5d7c32f9074d95860d2fb0b87610c7/e46b7b89bc8c409db09184416343fca3.jpg, createdBy=d20e5497900, createdName=乌云背后的幸福线, createdTime=Mon Dec 27 14:52:48 CST 2021, time=2021-12-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=805951, encodeId=59f08059514f, content=审稿速度:3.0 | 投稿命中率:25.0 经验分享：被别的期刊transfer到这里，想问问大家最近审稿一般多久啊, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=148, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20200804/b240f936e21e44bfbd965bfd8e0d8598/7ff50448cc364484b0350107a115d287.jpg, createdBy=66a35286254, createdName=Juldez822, createdTime=Mon Aug 03 17:46:11 CST 2020, time=2020-08-03, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=567765, encodeId=f79256e765de, content=请问朋友，你的文章一审多久才回的消息呢？我着急投，望告知一二，感谢，感谢，感谢！wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=wuszekei 2018-07-19 09:57:00 发表: if又降了，两个月前看还是2.401，现在是2.341，伤心……, objectType=tool_impact_factor, channel=null, level=null, likeNumber=247, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=19d42499443, createdName=124963ffm19(暂无昵称), createdTime=Thu Mar 07 00:00:00 CST 2019, time=2019-03-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=559357, encodeId=0b8255935e42, content=if又降了，两个月前看还是2.401，现在是2.341，伤心……, beContent=null, objectType=tool_impact_factor, channel=null, level=null, likeNumber=272, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://login.medsci.cn/upload/avatar/2cb9ad1a8e944b32a02af42a0ad515d1/38cbe7006bb07f875625a3f1da599d88.jpg, createdBy=f1452330065, createdName=wuszekei, createdTime=Thu Jul 19 09:57:00 CST 2018, time=2018-07-19, status=1, ipAttribution=)]

2018-07-19 wuszekei

if又降了，两个月前看还是2.401，现在是2.341，伤心……

272 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

期刊讨论

科室

工具

服务